A randomized, controlled phase 2/3 pivotal trial of bertilimumab in bullous pemphigoid

Trial Profile

A randomized, controlled phase 2/3 pivotal trial of bertilimumab in bullous pemphigoid

Planning
Phase of Trial: Phase II/III

Latest Information Update: 23 May 2018

At a glance

  • Drugs Bertilimumab (Primary)
  • Indications Bullous pemphigoid
  • Focus Registrational; Therapeutic Use
  • Sponsors Immune Pharmaceuticals Inc
  • Most Recent Events

    • 23 May 2018 According to Immune Pharmaceuticals media release, The Company is preparing for meetings with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) later this year to discuss the planned phase 2/3 study as well as important manufacturing plans
    • 15 May 2018 According to Immune Pharmaceuticals media release, the company is planning to discuss this trial with the FDA later in 2018.
    • 22 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top